The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE ...

BioXcel Therapeutics stock opened at $0.47 on Tuesday. BioXcel Therapeutics has a 1 year low of $0.30 and a 1 year high of $4.17. The firm’s 50-day moving average is $0.49 and its 200-day moving ...

In a report released today, Alec Stranahan from Bank of America Securities downgraded Bioxcel Therapeutics (BTAI – Research Report) to a Sell, with a price target of $0.25. The company’s ...